SCHEMBL7863563

SCHEMBL7863563

CCOC(=O)c1cnc2cccc(CCl)n12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 5/20 0.46
TGFBR1 P36897 1/20 0.42
GAA P10253 3/20 0.41
CYP1A2 P05177 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
KDM4E B2RXH2 2/20 0.39
GLA P06280 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP3A4 P08684 2/20 0.38
GABRA1 P14867 2/20 0.38
GABRB2 P47870 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL7863512 0.95 IDO1 (0.42) IDO1TGFBR1GAACYP1A2SMN1; SMN2
SCHEMBL8607422 0.88 IDO1 (0.45) IDO1TGFBR1GAACYP1A2SMN1; SMN2
Sulfuric Acid SCHEMBL8587675 0.85 GAA (0.38) IDO1TGFBR1GAACYP1A2SMN1; SMN2
SCHEMBL7875409 0.83 GAA (0.51) IDO1TGFBR1GAACYP1A2SMN1; SMN2
SCHEMBL8607762 0.82 IDO1 (0.41) IDO1TGFBR1GAACYP1A2SMN1; SMN2
SCHEMBL8607204 0.81 IDO1 (0.50) IDO1TGFBR1GAACYP1A2SMN1; SMN2
SCHEMBL12549868 0.81 CYP1A2 (0.43) IDO1TGFBR1GAACYP1A2SMN1; SMN2
SCHEMBL7872427 0.81 IDO1 (0.46) IDO1TGFBR1GAACYP1A2SMN1; SMN2
SCHEMBL8607489 0.79 IDO1 (0.46) IDO1TGFBR1GAACYP1A2SMN1; SMN2
SCHEMBL7863514 0.78 IDO1 (0.42) IDO1TGFBR1GAACYP1A2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010051631-A1 Tricyclic compounds, their production and use TAKATANI MUNEO (JP) 2001-12-13 US disclosed
US-6251905-B1 Tricyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-26 US disclosed
US-5958942-A HAVING EXCELLENT PDGF-INHIBITING ACTIVITIES, ANTIHYPERTENSIVE ACTIVITIES, ACTIVITIES OF AMELIORATING RENAL DISEASES AND ACTIVITIES OF LOWERING LIPID LEVEL. TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-09-28 US disclosed
WO-1998029136-A1 STABILIZED TRICYCLIC COMPOUND TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-07-09 WO disclosed
EP-0826686-A2 Tricyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-03-04 EP disclosed
US-5716964-A BRAIN DISORDERS; ANTIISCHEMIC AGENTS G.D. SEARLE & CO. (US) 1998-02-10 US disclosed
EP-0436831-A2 Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury G.D. Searle & Co. (US) 1991-07-17 EP disclosed
WO-1991008211-A1 IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY G.D. SEARLE & CO. (US) 1991-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051631-A1 Tricyclic compounds, their production and use PDGFA, HGF, REN IDO1 795/4885TGFBR1 174/4885GAA 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.